Evaluation of Jinlida Granules in Improvements to Standard-Reaching Rate of Blood Glucose and Type 2 Diabetes Mellitus Symptoms: Results of Secondary Analysis From 12-Week Trial
Abstract
Background
The previous study found that the Jinlida could significantly reduce levels of blood glucose and enhance the lowing-glucose action of metformin. However, the role of the standard-reaching rate of blood glucose and improving clinical symptoms in Jinlida has yet to be studied. We aimed to elaborate on the efficacy of Jinlida in Type 2 diabetics who experience clinical symptoms based on secondary analysis from the 12-week trial.
Methods
Data were analyzed from a 12-week, randomized, placebo-controlled, study of Jinlida. The standard-reaching rate of blood glucose, total symptom score, the efficacy of single symptom, symptom disappearance rate, symptom improvement rate was evaluated. Then, the correlation of the symptom effective rate and HbA1c was analyzed.
Results
192 T2DM patients were randomly allocated to receive either Jinlida or a placebo for 12 consecutive weeks. The standard-reaching rate of HbA1c (<6.5%) was 25% in the treatment group when compared to 14.9% in the control group. (P=0.046); All the symptom exhibited a change difference, comparing the treatment group to the control group after 12 weeks’ intervention. (P< 0.05); Hunger, polyuria, dry mouth, sweating and dysphoria in chestpalms-soles symptoms exhibited a change difference in the treatment group, compared to that in the control group. (P<0.05). All the symptom exhibited a significant difference in symptom improvement rate. (P<0.05).
Conclusions
Jinlida glandule can effectively improve clinical…
How strong is the evidence?
Evidence Hub reads this as a secondary / pooled analysis. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence. Reported size: 192 participants or records.
Read the paper
Related studies
- Metformin as an adjuvant in breast cancer treatment
- Metformin Lysosomal Targeting: A Novel Aspect to Be Investigated for Metformin Repurposing in Neurodegenerative Diseases?
- Aberrant HSF1 signaling activation underlies metformin amelioration of myocardial infarction in mice
- Metformin induces ZFP36 by mTORC1 inhibition in cervical cancer-derived cell lines
- Protein Interaction Network for Identifying Vascular Response of Metformin (Oral Antidiabetic)
- Preventing Long COVID With Metformin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.